Hydrocortisone and long-term outcomes in very-low-birthweight infants

Chika Yamasaki, Atsushi Uchiyama, Hidehiko Nakanishi, Kenichi Masumoto, Hiroyuki Aoyagi, Yousuke Washio, Satsuki Totsu, Ken Imai, Satoshi Kusuda

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The long-term effects of hydrocortisone (HDC) used for very-low-birthweight (VLBW) infants with chronic lung disease (CLD) are not fully understood. The aim of this study was to examine the short-term clinical effects and long-term impact of a physiological replacement dose of HDC on acute deterioration of CLD in VLBW infants. Methods: This prospective case-control study included 110 of the 174 VLBW infants admitted to our facility between 2003 and 2006 who were followed up to a corrected age of 18 months. Infant deaths and infants with congenital deformities were excluded from the study. The infants were classified into the following three groups: infants with CLD and treated with HDC (1-2 mg/kg/dose) due to progressive deterioration in oxygenation (CLD treatment group; n= 24); infants with CLD but not treated with HDC (CLD untreated group; n= 40); and infants without CLD (non-CLD group; n= 46). Results: The fraction of inspired oxygen (FIO2) in the CLD treatment group improved significantly after treatment (P <0.01). There were no significant differences among the three groups in terms of growth and neurodevelopmental quotient at the corrected age of 18 months following adjustment for birthweight, sex, and presence of light-for-date infants. There were also no significant intergroup differences in all three areas of developmental quotient. Conclusions: Physiological doses of HDC replacement are effective in treating acute deterioration in oxygenation in VLBW infants with CLD. Furthermore, this treatment modality did not adversely affect the growth and development of infants at the corrected age of 18 months.

Original languageEnglish
Pages (from-to)465-470
Number of pages6
JournalPediatrics International
Volume54
Issue number4
DOIs
Publication statusPublished - Aug 2012
Externally publishedYes

Fingerprint

Hydrocortisone
Lung Diseases
Chronic Disease
Therapeutics
Growth and Development
Case-Control Studies
Oxygen
Light
Growth

Keywords

  • chronic lung disease
  • glucocorticoid
  • neurodevelopmental outcome
  • oxygenation
  • preterm infants

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Yamasaki, C., Uchiyama, A., Nakanishi, H., Masumoto, K., Aoyagi, H., Washio, Y., ... Kusuda, S. (2012). Hydrocortisone and long-term outcomes in very-low-birthweight infants. Pediatrics International, 54(4), 465-470. https://doi.org/10.1111/j.1442-200X.2012.03601.x

Hydrocortisone and long-term outcomes in very-low-birthweight infants. / Yamasaki, Chika; Uchiyama, Atsushi; Nakanishi, Hidehiko; Masumoto, Kenichi; Aoyagi, Hiroyuki; Washio, Yousuke; Totsu, Satsuki; Imai, Ken; Kusuda, Satoshi.

In: Pediatrics International, Vol. 54, No. 4, 08.2012, p. 465-470.

Research output: Contribution to journalArticle

Yamasaki, C, Uchiyama, A, Nakanishi, H, Masumoto, K, Aoyagi, H, Washio, Y, Totsu, S, Imai, K & Kusuda, S 2012, 'Hydrocortisone and long-term outcomes in very-low-birthweight infants', Pediatrics International, vol. 54, no. 4, pp. 465-470. https://doi.org/10.1111/j.1442-200X.2012.03601.x
Yamasaki, Chika ; Uchiyama, Atsushi ; Nakanishi, Hidehiko ; Masumoto, Kenichi ; Aoyagi, Hiroyuki ; Washio, Yousuke ; Totsu, Satsuki ; Imai, Ken ; Kusuda, Satoshi. / Hydrocortisone and long-term outcomes in very-low-birthweight infants. In: Pediatrics International. 2012 ; Vol. 54, No. 4. pp. 465-470.
@article{87c3e23ec7074ea096675db0698c362c,
title = "Hydrocortisone and long-term outcomes in very-low-birthweight infants",
abstract = "Background: The long-term effects of hydrocortisone (HDC) used for very-low-birthweight (VLBW) infants with chronic lung disease (CLD) are not fully understood. The aim of this study was to examine the short-term clinical effects and long-term impact of a physiological replacement dose of HDC on acute deterioration of CLD in VLBW infants. Methods: This prospective case-control study included 110 of the 174 VLBW infants admitted to our facility between 2003 and 2006 who were followed up to a corrected age of 18 months. Infant deaths and infants with congenital deformities were excluded from the study. The infants were classified into the following three groups: infants with CLD and treated with HDC (1-2 mg/kg/dose) due to progressive deterioration in oxygenation (CLD treatment group; n= 24); infants with CLD but not treated with HDC (CLD untreated group; n= 40); and infants without CLD (non-CLD group; n= 46). Results: The fraction of inspired oxygen (FIO2) in the CLD treatment group improved significantly after treatment (P <0.01). There were no significant differences among the three groups in terms of growth and neurodevelopmental quotient at the corrected age of 18 months following adjustment for birthweight, sex, and presence of light-for-date infants. There were also no significant intergroup differences in all three areas of developmental quotient. Conclusions: Physiological doses of HDC replacement are effective in treating acute deterioration in oxygenation in VLBW infants with CLD. Furthermore, this treatment modality did not adversely affect the growth and development of infants at the corrected age of 18 months.",
keywords = "chronic lung disease, glucocorticoid, neurodevelopmental outcome, oxygenation, preterm infants",
author = "Chika Yamasaki and Atsushi Uchiyama and Hidehiko Nakanishi and Kenichi Masumoto and Hiroyuki Aoyagi and Yousuke Washio and Satsuki Totsu and Ken Imai and Satoshi Kusuda",
year = "2012",
month = "8",
doi = "10.1111/j.1442-200X.2012.03601.x",
language = "English",
volume = "54",
pages = "465--470",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Hydrocortisone and long-term outcomes in very-low-birthweight infants

AU - Yamasaki, Chika

AU - Uchiyama, Atsushi

AU - Nakanishi, Hidehiko

AU - Masumoto, Kenichi

AU - Aoyagi, Hiroyuki

AU - Washio, Yousuke

AU - Totsu, Satsuki

AU - Imai, Ken

AU - Kusuda, Satoshi

PY - 2012/8

Y1 - 2012/8

N2 - Background: The long-term effects of hydrocortisone (HDC) used for very-low-birthweight (VLBW) infants with chronic lung disease (CLD) are not fully understood. The aim of this study was to examine the short-term clinical effects and long-term impact of a physiological replacement dose of HDC on acute deterioration of CLD in VLBW infants. Methods: This prospective case-control study included 110 of the 174 VLBW infants admitted to our facility between 2003 and 2006 who were followed up to a corrected age of 18 months. Infant deaths and infants with congenital deformities were excluded from the study. The infants were classified into the following three groups: infants with CLD and treated with HDC (1-2 mg/kg/dose) due to progressive deterioration in oxygenation (CLD treatment group; n= 24); infants with CLD but not treated with HDC (CLD untreated group; n= 40); and infants without CLD (non-CLD group; n= 46). Results: The fraction of inspired oxygen (FIO2) in the CLD treatment group improved significantly after treatment (P <0.01). There were no significant differences among the three groups in terms of growth and neurodevelopmental quotient at the corrected age of 18 months following adjustment for birthweight, sex, and presence of light-for-date infants. There were also no significant intergroup differences in all three areas of developmental quotient. Conclusions: Physiological doses of HDC replacement are effective in treating acute deterioration in oxygenation in VLBW infants with CLD. Furthermore, this treatment modality did not adversely affect the growth and development of infants at the corrected age of 18 months.

AB - Background: The long-term effects of hydrocortisone (HDC) used for very-low-birthweight (VLBW) infants with chronic lung disease (CLD) are not fully understood. The aim of this study was to examine the short-term clinical effects and long-term impact of a physiological replacement dose of HDC on acute deterioration of CLD in VLBW infants. Methods: This prospective case-control study included 110 of the 174 VLBW infants admitted to our facility between 2003 and 2006 who were followed up to a corrected age of 18 months. Infant deaths and infants with congenital deformities were excluded from the study. The infants were classified into the following three groups: infants with CLD and treated with HDC (1-2 mg/kg/dose) due to progressive deterioration in oxygenation (CLD treatment group; n= 24); infants with CLD but not treated with HDC (CLD untreated group; n= 40); and infants without CLD (non-CLD group; n= 46). Results: The fraction of inspired oxygen (FIO2) in the CLD treatment group improved significantly after treatment (P <0.01). There were no significant differences among the three groups in terms of growth and neurodevelopmental quotient at the corrected age of 18 months following adjustment for birthweight, sex, and presence of light-for-date infants. There were also no significant intergroup differences in all three areas of developmental quotient. Conclusions: Physiological doses of HDC replacement are effective in treating acute deterioration in oxygenation in VLBW infants with CLD. Furthermore, this treatment modality did not adversely affect the growth and development of infants at the corrected age of 18 months.

KW - chronic lung disease

KW - glucocorticoid

KW - neurodevelopmental outcome

KW - oxygenation

KW - preterm infants

UR - http://www.scopus.com/inward/record.url?scp=84864397285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864397285&partnerID=8YFLogxK

U2 - 10.1111/j.1442-200X.2012.03601.x

DO - 10.1111/j.1442-200X.2012.03601.x

M3 - Article

VL - 54

SP - 465

EP - 470

JO - Pediatrics International

JF - Pediatrics International

SN - 1328-8067

IS - 4

ER -